Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks
ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor's nationwide expansion and broaden patient access to its immunotherapy-response diagnostics. Ascension Ventures, the strategic investment arm of 13 leading U.S. health systems across 22 states, representing more than $100. ...